Clinical Trials Logo

Filter by:
NCT ID: NCT04393038 Terminated - COVID-19 Clinical Trials

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Mir-Age
Start date: July 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2 (the MiR-AGE study).

NCT ID: NCT04392960 Recruiting - AL Amyloidosis Clinical Trials

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

Start date: July 22, 2020
Phase: N/A
Study type: Interventional

This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.

NCT ID: NCT04392908 Active, not recruiting - Memory Clinical Trials

Communication Memory of Cancer Diagnosis Within the Pediatric Triangle

Start date: September 1, 2019
Phase:
Study type: Observational

Present project aims to investigate memories related to a cancer communication diagnosis in pediatric oncology. It evaluates possible common elements and specificity between family and healthcare staff.

NCT ID: NCT04392557 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Anti-inflammatory Status in DM2 Treated Patients

INF-DM2-Ther
Start date: July 1, 2020
Phase: Phase 4
Study type: Interventional

Diabetes mellitus Type 2 (DMT2) - a progressive insulin secretory defect on the background of insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory disease of the arterial wall, in which leukocytes and oxidized lipoproteins accumulate leading to formation of fatty streaks and atherosclerotic plaques. Atherosclerosis accounts for more than 600,000 deaths annually in the U.S. mainly due to acute myocardial infarction and stroke. Pharmacological therapy of DMT2 includes several drugs used as monotherapy, although combination therapy between metfomin plus thiazolidinediones (TZD) and/or dipeptidyl-peptidase 4 inhibitors (DPP4I) plus TDZ, may delay atherosclerosis progression even if the molecular mechanisms are not clear. Even if normoglycemia is achieved, DMT2 patients still displayed a higher risk for developing atherosclerosis suggesting that other mechanisms of the inflammatory status are involved

NCT ID: NCT04392453 Completed - Stroke Clinical Trials

Upper Limb Robotic Rehabilitation During COVID-19 Outbreak

Start date: October 26, 2020
Phase: N/A
Study type: Interventional

The COVID-19 outbreak requires a rapid re-shaping of the entire organization of the rehabilitation services. This includes the design and planning of appropriate rehabilitation settings, intervention and logistics for organizing space for patients. The aims of this study are: (a) to evaluate the feasibility of the bedside use of a novel rehabilitation device for upper limb in patients with stroke; (b) to evaluate the motor and cognitive outcomes of the treatment; (c) to validate the instrumental outcomes provided by the device.

NCT ID: NCT04392245 Completed - Clinical trials for Proctologic Practice During COVID-19

Proctologic Practice and Covid-19

PROCTOLOCK
Start date: April 15, 2020
Phase:
Study type: Observational

Cross-sectional non-incentivized worldwide web survey. A worldwide survey of 1050 respondents showed that proctologic practice has been seriously affected by the pandemic. Age, gender and level of hospital preparedness predicted the change of status of surgical and outpatient activities. The results of our study may inform the development of strategies to reopen activities while protecting frontline healthcare workers.

NCT ID: NCT04391205 Completed - Clinical trials for Upper Extremity Deep Vein Thrombosis, Secondary

A Study to Investigate the Possible Causes of Secondary Effects During Use of Peripheral Midline Type Catheter in Patients Hospitalized in Different Care Settings

MIDES
Start date: April 26, 2017
Phase:
Study type: Observational

Although the use of peripheral venous catheters (CVP) with brachial insertion with echo-guide (Midline) has increased significantly over the last 5-10 years, there are no sensitive data concerning complications in the literature during their use, particularly as regards incidence of thrombotic complication.The prospective observational study will enroll all the patients admitted to Home Health Hospitalization service, Geriatric Department and Intermediate Care service, to whom a Midline-type CVP will be placed for infusional therapy and who will give their consent to participate.

NCT ID: NCT04390763 Terminated - Clinical trials for Metastatic Pancreatic Ductal Adenocarcinoma

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

daNIS-1
Start date: October 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in untreated mPDAC.

NCT ID: NCT04390113 Terminated - BK Virus Infection Clinical Trials

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

Start date: March 18, 2021
Phase: Phase 3
Study type: Interventional

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).

NCT ID: NCT04389372 Recruiting - Migraine Headache Clinical Trials

Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse

ChroMig-Smart
Start date: March 15, 2020
Phase: N/A
Study type: Interventional

Chronic Migraine is a disabling condition that affects the 2% of migraine population. It is often associated with medication overuse that makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse but it is also confirmed that patients have to be carefully followed in the last period after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic approach. It has been also reported how the clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication. Generally patients after withdrawal follow a specific prophylaxis for migraine, but also come weekly to the hospital for practicing mindfulness for 6 sessionsAs the emergency situation due to the Corona-virus pandemic phenomenon in Italy, patients will miss the possibility to come for the regular practice to the hospital: for this reason the investigator propose a small pilot study to enforce the use of technology for our patients so that they can continue to be followed in their therapeutic process. This preliminary study will be conducted on 25 patients that have been submitted to a withdrawal according to the standard procedure at our hospital and they will practice mindfulness daily by a standard session of 12 minutes on their smartphone recorded by the expert who generally manage their sessions at the hospital and also a weekly video-call to evaluate the clinical condition and to encourage to use strategies for pain management. This modality will allow the patients to continue their therapeutic process and to be followed regularly during the one year after withdrawal